P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial

被引：0
|
作者：
Genovese, Mark C. [1 ]
Lertratanakul, Apinya [2 ]
Anderson, Jaclyn [2 ]
Papp, Kim [3 ]
Tillett, William [4 ]
van den Bosch, Filip [5 ]
Tsuji, Shigeyoshi [6 ]
Dokoupilova, Eva [7 ]
Keiserman, Mauro [8 ]
Wang, Xin [2 ]
Zhong, Sheng [2 ]
Zueger, Patrick [2 ]
Pangan, Aileen [2 ]
Mease, Philip [9 ,10 ]
机构：
[1] Stanford Univ, Sch Med, Dept Immunol & Rheumatol, Palo Alto, CA USA
[2] AbbVie Inc, Med, N Chicago, IL USA
[3] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
[4] Royal Natl Hosp Rheumat Dis, Rheumatol, Bath, Avon, England
[5] Ghent Univ Hosp, Dept Internal Med, Ghent, Belgium
[6] Osaka Minami Med Ctr, Dept Orthopaed Rheumatol, Osaka, Japan
[7] Uherske Hradiste & Univ Vet & Pharmaceut Sci, Med Plus, Brno, Czech Republic
[8] Pontificia Univ Catolica, Sch Med, Porto Alegre, RS, Brazil
[9] Swedish Med Ctr, Dept Rheumatol, Seattle, WA USA
[10] Univ Washington, Seattle, WA 98195 USA
来源：
RHEUMATOLOGY | 2021年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Deodhar, Atul
    Van den Bosch, Filip
    Poddubnyy, Denis
    Maksymowych, Walter P.
    van der Heijde, Desiree
    Kim, Tae-Hwan
    Kishimoto, Mitsumasa
    Blanco, Ricardo
    Duan, Yuanyuan
    Li, Yihan
    Pangan, Aileen L.
    Wung, Peter
    Song, In-Ho
    LANCET, 2022, 400 (10349): : 369 - 379
  • [32] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
    Deodhar, A.
    Van den Bosch, F.
    Poddubnyy, D.
    Maksymowych, W. P.
    Van der Heijde, D.
    Kim, T. H.
    Kishimoto, M.
    Duan, Y.
    Li, Y.
    Pangan, A.
    Wung, P.
    Song, I. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 9 - 10
  • [33] Randomised clinical trial: A double-blind, randomised, active-controlled, phase 3 study to evaluate the safety and efficacy of Tegoprazan in patients with gastric ulcer
    Choe, YoungHee
    Cho, YuKyung
    Lim, ChulHyun
    Choi, Myung-Gyu
    NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32
  • [34] Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
    Langley, R. G.
    Tsai, T. -F.
    Flavin, S.
    Song, M.
    Randazzo, B.
    Wasfi, Y.
    Jiang, J.
    Li, S.
    Puig, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 114 - 123
  • [35] Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study (vol 393, pg 2303, 2019)
    Smolen, J. S.
    Pangan, A. L.
    Emery, P.
    LANCET, 2019, 393 (10191): : 2590 - 2590
  • [36] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
    Deodhar, Atul
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth C.
    LANCET, 2018, 391 (10136): : 2213 - 2224
  • [37] Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
    Meininger, Vincent
    Genge, Angela
    van den Berg, Leonard H.
    Robberecht, Wim
    Ludolph, Albert
    Chio, Adriano
    Kim, Seung H.
    Leigh, P. Nigel
    Kiernan, Matthew C.
    Shefner, Jeremy M.
    Desnuelle, Claude
    Morrison, Karen E.
    Petri, Susanne
    Boswell, Diane
    Temple, Jane
    Mohindra, Rajat
    Davies, Matt
    Bullman, Jonathan
    Rees, Paul
    Lavrov, Arseniy
    LANCET NEUROLOGY, 2017, 16 (03): : 208 - 216
  • [38] Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
    Mease, Philip J.
    Lertratanakul, Apinya
    Papp, Kim A.
    van den Bosch, Filip E.
    Tsuji, Shigeyoshi
    Dokoupilova, Eva
    Keiserman, Mauro W.
    Bu, Xianwei
    Chen, Liang
    McCaskill, Reva M.
    Zueger, Patrick
    McDearmon-Blondell, Erin L.
    Pangan, Aileen L.
    Tillett, William
    RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 903 - 919
  • [39] Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
    Philip J. Mease
    Apinya Lertratanakul
    Kim A. Papp
    Filip E. van den Bosch
    Shigeyoshi Tsuji
    Eva Dokoupilova
    Mauro W. Keiserman
    Xianwei Bu
    Liang Chen
    Reva M. McCaskill
    Patrick Zueger
    Erin L. McDearmon-Blondell
    Aileen L. Pangan
    William Tillett
    Rheumatology and Therapy, 2021, 8 : 903 - 919
  • [40] UPADACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF A SELECTIVE JAK1 INHIBITOR
    Genovese, M. C.
    Fleischmann, R.
    Combe, B.
    Hall, S.
    Zhang, Y.
    Zhou, Y.
    Mohamed, M. F.
    Meerwein, S.
    Pangan, A. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 970 - 970
12345